Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. by Hamdy, F. C. et al.
Br. J. Cancer (1994), 69, 177 182
© Macmillan Press
Matrix metalloproteinase 9 expression in primary human prostatic
adenocarcinoma and benign prostatic hyperplasia
F.C. Hamdy'3, E.J. Fadlon3, D. Cottam5, J. Lawry3, W. Thurrell2, P.B. Silcocks4,
J.B. Anderson', J.L. Williams' & R.C. Rees3
Departments of'Urology and 2Pathology, Royal Hallamshire Hospital, Sheffield S10 2JF; 3Institutefor Cancer Studies and
4Department ofPublic Health Medicine, University ofSheffield Medical School, Sheffield S1O 2RX, UK; 5Department ofHealth
and Human Services, Bethesda, 900 Rockville Pike, Maryland, USA.
Summary Matrix metalloproteinase (MMP) expression was investigated in patients with prostatic adenocar-
cinoma and benign prostatic hyperplasia (BPH). Forty-one men were studied: 26 had histologically proven
prostate cancer, with 14 (54%) showing metastatic disease; 15 patients had BPH. Prostatic tissue was obtained
from transurethral resection and needle core biopsies; gelatinolytic activity was determined by zymography.
Seven gelatinolytic bands were detected, with molecular weights ranging from > 100 kilodalton (kDa) to
29 kDa. Nine of 14 patients (64%) with skeletal metastases had 92 kDa activity, present in only two of 12
patients (17%) with a negative bone scan, and absent in BPH. The 92 kDa gelatinolytic activity was expressed
in 73% of aneuploid tumours compared with 20% of diploid tumours. A 97 kDa gelatinase was expressed in
80% of BPH samples and 23% of carcinoma patients. Enzyme bands of 72, 66 and 45 kDa were equally
expressed in malignant tissue, irrespective of metastatic status, but were expressed in fewer BPH patients. The
97, 92, 66 and 45 kDa enzymes were identified as being pro-MMP-9 sequences by Western blotting, using a
specific antibody directed against the pro sequence of the mature protein. MMP activity appeared to be
increased in malignant prostatic tissue compared with BPH. Pro-MMP-9, in its 92 kDa form, was shown to be
exclusively expressed by malignant prostatic tissue, and in particular by tumours that exhibited the aggressive
and metastatic phenotype.
Prostate cancer is the third most common malignancy in men
in England and Wales, with over 9,000 new cases registered
every year (Office of Population Censuses and Surveys, 1985).
Approximately 50% of patients present with metastatic
disease and have a poor prognosis, with a median survival of
less than 3 years (Whitmore, 1984). By contrast, a 5-year
survival rate of up to 93% can be expected in those patients
with localised disease which fails to progress beyond the
confines of the gland (George, 1988; Johansson et al., 1989,
1992). Autopsy studies have also shown that many men over
the age of 80 harbour a prostatic cancer which never
becomes clinically manifest (Hirst & Bergman, 1954). The
reason for such discrepancies in the presentation and subse-
quent behaviour of prostate cancer remains unclear, and
represents a great challenge to clinicians and scientists.
Attempts have been made to predict the biological
behaviour of prostate cancer. While tumour staging and
volume, serum prostate-specific antigen (PSA) measurements,
histopathological grading and deoxyribonucleic acid (DNA)
tumour ploidy status have all be shown to correlate with
prognosis and survival (Tavares et al., 1973; de Vere White &
Deitch, 1989; Gittes, 1991), no single method can reliably
distinguish between potentially progressing tumours and
those which will remain quiescent. New reliable criteria are
thus needed to define the invasive and metastatic potential of
individual prostate cancer cases. This has prompted the pre-
sent research to be undertaken into the potential value of
matrix metalloproteinase (MMP) expression in predicting
metastatic disease in prostate cancer.
To date, five subgroups of MMP have been identified
(MMP-1 and -8, MMP-3 and -10, MMP-7, MMP-2 and -9,
MMP- 11), depending on the relationship of each enzyme to
bacterial zinc-containing proteinases (Murphy et al., 1991;
Woessner, 1991; Cottam & Rees, 1993). The MMP family
can also be divided into three subclasses according to
homology and substrate specificity; these are the gelatinases
(type IV collagenases), the stromelysins and the interstitial
collagenases (Matrisian, 1990). MMPs are involved in both
physiological processes, including embryonic development,
post-partum uterine involution, ovulation and wound heal-
ing, and in pathological conditions, including rheumatoid
arthritis and tumour invasion. Some members of the MMP
family of enzymes are capable of degrading basement memb-
rane (BM) at the tumour-host interface, with variable
enzyme production correlating with the metastatic phenotype
(Liotta, 1986; Murphy et al., 1989). Expression of these
enzymes is now accepted as a universal important step in the
metastatic cascade of events of a primary malignant tumour.
Furthermore, the activity of MMP in tissues is regulated by a
group of specific inhibitors: the tissue inhibitors of metallo-
proteinases (TIMP-1 and TIMP-2). It is the fine balance
between MMP and TIMP expression which will determine, in
part, the invasive ability of a given cancer cell (Liotta &
Stetler-Stevenson, 1991; Liotta et al., 1991).
Several reports have recently been emerging in the
literature, correlating MMP expression and tumour
invasiveness in prostate cancer. Using Northern blotting to
study MMP gene expression in benign and malignant pros-
tatic tissue, Pajouh et al. (1991) found that MMP-7 was
increased in malignant compared with benign prostatic tissue,
but absent in the stroma; and that type I collagenase and
stromelysins were also present in prostate cancer tissue. Boag
and Young (1993) found increased levels of the 72 kDa type
IV collagenase in malignant prostate and metastatic tissue by
immunohistochemistry. Stearns and Wang (1993) analysed
BPH and primary prostate cancer tissue extracts for type IV
collagenase (Mr 72,000) expression, using collagenase
antibodies and Northern blot studies. Their results suggested
that the enzyme is selectively overexpressed by malignant and
preinvasive epithelial cells, with low levels in benign tissue
and the stroma surrounding tumour foci. Powell et al. (1993)
have demonstrated increased invasiveness of the prostate
cancer cell line DU-145 following transfection with Mat-
rilysin metalloproteinase (MMP-7). A more recent study by
Wilson et al. (1993) investigated gelatinolytic and caseinolytic
proteinase activities in human prostatic secretions, showing a
variety of proteinase activity with differential levels of expres-
sion in neoplastic compared with benign disease.
In the present study, zymography and Western blotting
were used to investigate MMP gelatinolytic activity, and to
compare MMP-9 expression patterns in tissue extracts from
prostate cancer and BPH; the findings were correlated with
Correspondence: F.C. Hamdy, Department of Urology, Freeman
Hospital, High Heaton, Newcastle upon Tyne, NE7 7DN, UK.
Br. J. Cancer (1994), 69, 177-182 '." Macmillan Press Ltd., 1994178 F.C. HAMDY et al.
clinical data collected from each patient. The results and the
possible role of MMP-9 expression in identifying potentially
progressing tumours are discussed.
Patients and methods
Patients
Forty-one patients were studied. Their age ranged from 46 to
87 years (median 68 years). Fifteen patients had BPH and 26
had histologically proven prostatic adenocarcinoma. All
patients had three serial serum prostate-specific antigen
(PSA) measurements (immunometric radioimmunoassay,
CIS, UK) prior to prostatic manipulation, and patients with
prostate cancer had a technetium-99m bone scan prior to
commencement of the study. Patients with metastatic disease
were treated by hormonal manipulation, in the form of
bilateral orchidectomy or administration of a luteinising
hormone-releasing hormone (LHRH) analogue. Patients with
disease apparently localised to the prostate were treated with
external beam irradiation. The follow-up period ranged from
4 to 18 months (median 10 months).
Sample preparation
Prostatic tissue was obtained from transurethral resection
specimens. Presence of carcinoma was confirmed by using
standard histological criteria and the combined Gleason
system of scoring 1 to 10 (Gleason, 1966; Gleason & Mell-
inger, 1974). Each tissue sample was collected in a sterile
plastic container, placed on ice and transported to the
laboratory within 30 min. Specimens were minced into 1 mm
cubes with crossed scalpels. Representative diced samples
were taken for histological examination by one observer
(W.T.), and for DNA analysis. DNA ploidy status was
measured by flow cytometry (Ortho Diagnostic Orthocyte),
using propidium iodide (DNA CycleTest, Becton-Dickinson,
UK) on at least 10,000 cells per sample of one million cells,
after filtration and mechanical dissociation to obtain single-
cell suspensions. DNA ploidy and cell cycle measurements
were made using the Multicycle DNA Analysis Computer
Package (Phoenix Flow Systems, USA) with samples ex-
cluded if coefficients of variations (CV) were greater than 10.
Remaining specimens were placed in glass homogenisers in a
threefold weight/volume of lysis buffer consisting of 50 mM
Tris-HCl pH 7.4 with 200 mm sodium chloride and 0.1%
Triton X-100. Homogenised samples were then centrifuged,
supernatant pipetted off and used immediately for zymo-
graphy. Protein content of each sample was determined by
the modified Lowry method (Wang & Smith, 1975), and
ranged from 2.3 to 3 tg per sample (average 2.5jLg).
Zymography
Gelatinolytic enzyme species were detected using zymography
as previously described (Heussen & Dowdle, 1980). Super-
natant samples were electrophoresed (200 volts for 36 min at
room temperature) in 7.5% polyacrylamide resolving gels
containing 1 mg ml-' gelatin, using Bio-Rad Mini Protean II
equipment (Bio-Rad, Richmond, CA, USA). The class of
gelatinolytic proteinases was determined by addition of
specific proteinase inhibitors into incubation buffer: 10 mM
ethylenediaminetetraacetic acid (EDTA) for metal ion-
dependent gelatinases, e.g. metalloproteinases, and 2 mM
phenylmethylsulphonylfluoride (PMSF) for serine pro-
teinases. Apparent molecular weight values were determined
by comparison with reduced molecular weight markers pre-
pared by addition of 2.5% 2-mercaptoethanol to the sample
buffer, followed by boiling for 3 min. Molecular weight
markers appeared as dark bands against a blue background,
and consisted of carbonic anhydrase (29 kDa), egg albumin
(45 kDa), bovine serum albumin (66 kDa) and phosphorylase
b (97 kDa) at a concentration of I mg ml' (Sigma, Poole,
UK).
Twenty microlitres of sample supernatant, in a buffer solu-
tion containing 0.25 M Tris-HCl pH 6.8, 0.4% sodium
dodecylsulphate and 34% glycerol, was loaded onto gels.
After electrophoresis, gels were washed with 2% Triton X-
100 for 1 h, followed by two 5 min washes in 50 mM
Tris-HCl pH 7.4 containing 200 mM sodium chloride and
5 mm calcium chloride, then incubated for 48 h at 37°C.
Enzymatic degradation was detected by staining gels with
0.1% (w/v) solution of Coomassie blue R250 in methanol -
acetic acid - water (3:1:6). Enzyme activity was visualised as
transparent bands against a blue background. After initial
detection of different molecular weight bands of activity,
gelatinolytic enzymes were activated in repeat experiments,
incubating the samples with 1 mM para-aminophenylmercuric
acetate (p-APMA) for 4 h at 37°C prior to zymography.
p-APMA, an organomercurial compound, activates BM-
degrading MMPs to the active lower molecular weight form
by cleavage of the propeptide fragment from the amino
terminus (Stetler-Stevenson et al., 1989).
Preparation ofMMP-9-specific antibody
Antibodies specific for-unique amino acid sequences present
in the propeptide domains of the MMP-9 molecule were
generated in-house and prepared as follows. A 20-mer pep-
tide selected from human 92 kDa gelatinase (aa) was syn-
thesised and purified by reversed-phase high-performance
liquid chromatography on a C18 column. Where indicated a
cysteine was added to the carboxy terminus ofthe peptide for
ease of coupling to the carrier protein. The peptide was
conjugated to keyhole limpet haemocyanin (KLH) (Sigma).
Free KLH was separated from KLH-peptide following
chromatography on a G-25 column. The polyclonal antipep-
tide antibody was produced in New Zealand White rabbits
using Freund's complete adjuvant. Antibody production pro-
tocols were performed according to UK Home Office regula-
tions. The immunoglobulin G (IgG)-containing fraction was
purified using Affi-gel Blue DEAE-cellulose (Bio-Rad, UK),
followed by chromatography on a protein A-Sepharose col-
umn. The amino acid sequence prepared for MMP-9 was:
RQRQSTLVLFPGDLRTN
The antibody was shown to be specific for the prosequence of
MMP-9. By immunoblotting, this antibody did not cross-
react with the active MMP-9 enzyme, MMP-2 pro- and
active enzyme, or other enzyme species.
Immunoblotting
Reduced and non-reduced protein samples were separated on
7.5% acrylamide gels followed by transfer onto PVDF
(polyvinylidenedifluoride) membranes (Bio-Rad, UK), fol-
lowing previously described protocols (Laemmli, 1970; Tow-
bin et al., 1979). Tris-buffered saline (TBS) (BioRad, UK)
equilibrated membranes were blocked for 2 h in 5% non-fat
milk-TBS (0.05% v/v) - Tween 20 (BioRad, UK), followed by
overnight incubation with 5% non-fat milk-TBS (0.05% v/v)
- Tween 20 and rabbit anti-human primary antibody, which
recognised the prosequence of mature MMP-9, as described
above. Subsequent steps were carried out with a BioRad
Western Blot detection kit using the enclosed protocol.
Statistical analysis
Statistical values were obtained using the chi-squared (x2) test
(Stat-X-ACT, Cytel Software, Cambridge, MA, USA). An
adjustment was made for multiple comparison by comparing
paring all P-values with a critical value of 0.0042 rather than
the usual 0.05. This value was obtained by a modified
Bonferroni method in which, instead of dividing the P-value
by the number of significance tests performed, it is divided by
an estimate of the number of true null hypotheses tested. The
latter was found to be approximately 12, using the graphical
method of Schweder and Spjotvoll (1982).MMP EXPRESSION IN PROSTATE CANCER 179
Results
Technetium-99 m isotope bone scans showed increased
uptake in 14 of 26 patients with prostate cancer, confirming
the presence of skeletal metastases in 53.8% of the cancer
population studied. DNA ploidy of malignant prostatic tis-
sue, measured by flow cytometry, showed that 11 of 26
patients (42%) had aneuploid primary tumours; the remain-
ing tumours were diploid. Five patients with locally advanced
and metastatic disease failed to respond to treatment in the
form of hormonal manipulation and died within 6 months of
commencement of the study. The remaining patients showed
a good immediate response to treatment, with symptomatic
improvement and reduction in serum PSA levels.
Using supernatants prepared from BPH or prostatic
adenocarcinoma tissue lysates, a maximum of seven
gelatinolytic bands were detected by zymography, ranging
from 29 kDa to > 100 kDa. A summary of the patterns of
expression in the different groups of patients and statistical
significance is shown in Tables I and II.
The high molecular weight band (>100 kDa) of enzyme
activity was predominantly present in patients with a
negative bone scan (75%) and in only 36% of patients with
BPH. While the 97 kDa gelatinolytic band was mostly pres-
ent in BPH samples (80%) and in an average 23% of malig-
nant tissue (P<0.001), the 92 kDa band was absent from
BPH tissue on zymography, but present in, on average, 42%
of cancer patients (P<0.004), 64% of patients with a
positive bone scan and 17% of those without metastases
(P<0.05) (Figure 1). Enzyme activities at molecular mass
(Mr) 72, 66 and 45 kDa were expressed in 77% of carcinomas
but only 27% (P<0.004), 20% (P<0.001) and 33%
(P<0.01) of BPH samples respectively. A 29kDa band of
activity was present in a minority of patients with carcinoma,
irrespective of their metastatic status, but was absent in BPH
patients. All degradation bands appearing in gelatin zymo-
grams were inhibited by EDTA, unaffected by PMSF and
showed a decrease in molecular weight following p-APMA
activation, suggesting that enzymes detected belonged to the
MMP family.
When enzyme activities obtained by gelatin zymography
were correlated with primary tumour ploidy (Table III), as
measured by flow cytometry, it became apparent that the
92 kDa band of enzyme activity was present in 73% of
patients with aneuploid tumours compared with only 20% of
patients with diploid tumours. The other bands of enzyme
activity were equally expressed in both groups, apart from
the high molecular weight enzyme, which was present in
nearly three times as many diploid tumours as aneuploid
tumours (statistically not significant). Expression of the
92 kDa gelatinase activity also correlated with other clinical
parameters, such as serum PSA levels, Gleason score and
immediate response to treatment. In these patients, the
median serum PSA value was 52.5 yg 1-', and mean Gleason
score was 7. Eighty-two per cent of patients had a positive
bone scan, and 73% of primary tumours were aneuploid. In
addition, the 92 kDa gelatinase activity was expressed in all
five patients who did not respond to treatment and died
within 6 months from inclusion in the study. Table IV sum-
marises the results. Western blotting, using a non-specific
rabbit antiserum prepared against the propeptide of MMP-9,
confirmed that 97, 92, 66 and 45 kDa gelatinolytic activities
represented different sequences of pro-MMP-9 (Figure 2).
Discussion
The key step in the natural history of cancer is the malignant
transformation of a normal cell. However, the most impor-
kDa
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Figure 1 Example of zymograms showing different gelatinolytic
bands of activity. Lanes 1 and 2 represent BPH; lanes 3, 4 and 5
represent primary prostatic adenocarcinoma. The 97/92 kDa
gelatinase pattern of activity is illustrated.
Table I Gelatinolytic matrix metalloproteinase (MMP) degradation bands obtained
from tissues of patients with prostatic adenocarcinoma (n = 26) and benign prostatic
hyperplasia (BPH, n = 15)
MMP degradation bands (M,, kDa)
>100 97 92 72 66 45 29
Carcinoma 14/26 6/26 11/26 20/26 20/26 20/26 5/26
n = 26 (54%) (23%) (42%) (77%) (77%) (77%) (19%)
BPH 3/15 12/15 0/15 4/15 3/15 5/15 0/15
n = 15 (20%) (80%) (0%) (27%) (20%) (33%) (0%)
Exact P 0.05 0.0008 0.003 0.002 0.0008 0.008 0.13
(Critical P value = 0.0042).
Table H Relationship between gelatinolytic matrix metalloproteinase (MMP)
degradation bands obtained from tissues of patients with prostatic adenocarcinoma
and a positive (CaP BS + ve, n = 14) and negative (CaP BS -ve, n = 12) bone
scan
MMP degradation bands (Mr. kDa)
>100 97 92 72 66 45 29
CaP BS+ve 5/14 4/14 9/14 10/14 11/14 12/14 2/14
n = 14 (36%) (29%) (64%) (71%) (79%) (86%) (14%)
CaP BS-ve 9/12 2/12 2/12 10/12 9/12 8/12 3/12
n = 12 (75%) (17%) (17%) (83%) (75%) (67%) (25%)
Exact P 0.082 0.650 0.021 0.652 1.000 0.365 0.635180 F.C. HAMDY et al.
Table III Relationship between gelatinolytic matrix metalloproteinase (MMP)
degradation bands and tumour DNA ploidy in 26 patients with prostatic
adenocarcinoma
MMP degradation bands (Mr, kDa)
>100 97 92 72 66 45 29
Aneuploid 3/11 2/11 8/11 9/11 7/11 9/11 0/11
(n = 11) (27%) (18%) (73%) (82%) (64%) (82%) (0%)
Diploid 11/15 4/15 3/15 11/15 13/15 11/15 5/15
(n = 15) (73%) (27%) (20%) (73%) (87%) (73%) (33%)
Differences are not statistically significant.
Table IV Patients with prostate cancer expressing the 92 kDa
metalloproteinase
Patient Bone Serum PSA Gleason
no. scan Ploidy (,Ig1-') score Outcome
1 + ve A 10.0 9 NR
2 +ve A 79.0 9 NR
3 +ve A 61.5 7 A & W
4 +ve D 16.4 6 A & W
5 + ve A 120.0 8 NR
6 +ve A 72.0 8 A & W
7 +ve A 39.0 6 A & W
8 + ve A 120.0 7 NR
9 +ve A 22.0 9 NR
10 -ve D 52.5 5 A & W
11 -ve D 42.0 6 A & W
NR, non-responder; A & W, alive and well; A, aneuploid tumour;
D, diploid tumour; + ve, positive; -ve, negative.
kDa- |XX 3 1|S|1
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Figure 2 Example of Western blot profile. Lane 1, BPH; lanes 2
and 3, primary prostatic adenocarcinoma.
tant event in the history of any given tumour is the forma-
tion of metastases. It is the ability of a malignant cell to
invade and metastasise which determines prognosis; if this is
unfavourable, early intervention is necessary to effectively
attempt a complete cure. In prostate cancer, metastasis is a
major cause of morbidity and mortality (Whitmore, 1984),
with many tumours being difficult to treat because of their
unpredictable behaviour and the inability of current investi-
gative methods to detect cancers with aggressive and meta-
static potential.
Invasion and metastasis are complex and multisequential
processes, accomplished by selected subpopulations of malig-
nant cells escaping from the primary tumour (Fidler & Hart,
1982; Fidler, 1991). The ability of tumour cells to migrate
across the BM and to degrade extracellular matrix (ECM)
occurs through the action of a series of degradative enzymes
produced by tumour cells (Tissot et al., 1984; Brown et al.,
1990), or following stimulation of host stromal cells to
release degradative enzymes by the tumour itself (Basset et
al., 1990). Data from animal and experimental studies sug-
gest a 'three-step theory' of tumour invasion (Liotta et al.,
1977; Liotta, 1986). The first step involves tumour cell
attachment to BM components via specific cell-surface recep-
tors, such as laminin. This is followed by proteolytic enzyme
expression by tumour cells to degrade ECM components,
particularly type IV collagenases belonging to the MMP
family, of which MMP-2 and MMP-9 are specific for type IV
collagen. The final step is tumour cell locomotion into the
region of the matrix modified by proteolysis.
The MMP family appears to assume increasing impor-
tance, in terms of its correlation with the metastatic
phenotype in experimental and animal models (Murphy et
al., 1989; Cottam & Rees, 1993). Several studies have
analysed MMP-2 (72 kDa) and MMP-7 expression in tissue
extracts from benign and malignant prostatic tissue, in pros-
tate cancer cell lines and in animal experimental models,
demonstrating increased activity in neoplastic compared with
benign tissue, and a direct correlation with the invasive
phenotype (Pajouh et al., 1991; Boag & Young, 1993; Powell
et al., 1993; Steams & Wang, 1993). However, to our know-
ledge, the current report is the first to describe a correlation
between MMP-9 expression and aggressive prostate cancer.
The study represents a novel approach in the search for
parameters to define the metastatic potential of prostate
cancers. Experimental findings provide an insight into the
ability of malignant prostatic and BPH tissue to express
gelatinolytic activity potentially involved in tissue invasion.
This further suggests that there may be important differences
in patterns of enzyme expression between benign and malig-
nant prostatic tissue.
From the results presented, it appears that MMP
gelatinolytic enzyme activity detected by zymography is in-
creased in malignant compared with benign prostatic tissue,
with the exception of a 97 kDa species. In contrast a 92 kDa
gelatinase was not expressed in benign tissue, but was
detected in 42% of carcinomas. With adjustments made for
multiple comparisons, statistical analysis suggests that the
highlighted results are real. Western blotting confirmed that
both 97 and 92 kDa activity represent the same enzyme,
which in its 97 kDa form in BPH may be represented as a
92 kDa species by activation, once malignant transformation
occurs, and processes of invasion and metastasis are in
motion, thus exhibiting a reduced molecular weight. In sup-
port of this theory, patients who exhibited 92 kDa gelatinase
activity in vitro had particularly unfavourable clinical
parameters, including well-established prognostic factors such
as high Gleason scores and serum PSA levels and primary
tumour DNA ploidy. Sixty-four per cent of patients with
positive bone scans expressed the 92 kDa enzyme, while only
17% of bone scan-negative patients were positive. Further-
more, the five patients in the cancer series studied who did
not respond to treatment were all included in the group
expressing the 92 kDa band. The 97 kDa gelatinolytic activity
may be attributable to a complex between pro-MMP-9 and
other proteins, while it is difficult, at this stage of the study,MMP EXPRESSION IN PROSTATE CANCER 181
to speculate on the nature of the high molecular weight
activity (> 100 kDa) detected in both BPH and carcinomas.
This may well represent a different gelatinase, a glycosylation
variant or an enzyme complex and remains to be identified,
possibly by enzyme purification methods. Detection by
Western blotting of further processed lower molecular weight
pro-MMP-9 sequence fragments in tumour lysates suggests
that tumour but not BPH tissue is capable of processing
MMP-9 intracellularly prior to secretion, with possible imp-
lications in the activity of the enzyme in vivo; this remains to
be determined. From the present study, in view of the
heterogeneity of the tissue samples analysed and the difficulty
in separating prostatic cancer cells from the surrounding
stroma and fibroblasts, it is impossible to assume that all the
enzymes detected were produced solely by tumour cells.
Indeed, it has been shown from work on breast cancer and in
skin tumours that stromal cells surrounding tumour foci can
be the main source of proteolytic enzyme synthesis (Basset et
al., 1990; Karelina et al., 1993). This may well be the case in
the work presented herein, and can only be determined by
further studies using in situ hybridisation and immunohis-
tochemistry. Furthermore, the gelatinase activity was
detected in vitro, and may not necessarily represent in vivo
behaviour, which could be affected in particular by specific
protease inhibitors, including TIMP-1 and TIMP-2. This may
constitute important further work to validate the present
findings in the in vivo situation.
The 92 kDa pro-MMP-9 is an immunologically distinct
glycosylated enzyme, mainly expressed by monocytes, mac-
rophages and polymorphonuclear leucocytes in the presence
of inflammation, and by tumour cells (Yamagata et al., 1988,
1989; Murphy et al., 1989). It is possible that the increased
92 kDa expression found in malignant prostatic samples
investigated in this study is merely the reflection of increased
inflammation in tumour tissue compared with BPH. How-
ever, histopathological examination of representative tissue
samples subjected to zymography did not consistently reveal
the presence of prominent inflammatory infiltrates in all the
specimens analysed. The 92 kDa enzyme is also known to be
frequently expressed by malignant tumours (Pyke et al., 1992;
1992; Sato et al., 1992), and can be induced by ras oncogene
transfection (Ballin et al., 1988). It has been correlated with
increasing metastatic potential and invasive behaviour in a
number of malignant cell types (Yamagata et al., 1988; Sato
& Seiki, 1993), and with the metastatic phenotype in trans-
formed rat embryo cells (Bernhard et al., 1990). Data from
these studies largely support the present findings, suggesting
a possible correlation between 92 kDa MMP expression and
aggressive prostate cancers.
Results obtained from this study warrant further investiga-
tion into the potential use of differential MMP expression as
new prognostic markers in prostate cancer, and as possible
predictor of clinical response to treatment. Further work
extending the present investigation to cellular and molecular
levels will further our understanding of the ubiquitous
biology of prostatic adenocarcinoma. Such studies may, in
future, identify a group of prostate cancer patients whose
tumours carry definite metastatic potential. This would
enable aggressive treatment to be directed at those most at
risk of developing progressive disease, in an attempt to
decrease the morbidity and mortality associated with this
common malignancy.
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